Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 49Brain Neoplasms 25Central Nervous System Neoplasms 22Astrocytoma 17Glioma 15Medulloblastoma 11Neoplasms 8Oligodendroglioma 7Recurrence 6Gliosarcoma 6Spinal Cord Neoplasms 2Ependymoma 2Sarcoma 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Newly Diagnosed High Grade Glioma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Familial ependymoma 1Drug-Related Side Effects and Adverse Reactions 1Diffuse Intrinsic Pontine Glioma 1

Interventions

motexafin gadolinium 1Spinal Puncture 1Lomustine 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Recurrence, Local × Lomustine × CNS × Clear all
NCT07100730 2026-04-16

IPAX BrIGHT

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
50 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local, Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡